I am very
pleased to see the article “Ondansetron in Pregnancy and Risk ofAdverse Fetal Outcomes” in the New England Journal for two reasons:
1. Drugs generally
aren’t tested on pregnant women during clinical trials, so for most drugs (and
food additives: see the recent FDA warning on SimplyThick), we just have no
idea whether they’re safe for pregnant women or not.
2. This is a negative result (no difference
between the women who took the drug and the control). Many journals are biased against publishing
negative results, because they’re thought to be uninteresting, but knowing that
a drug is safe is actually really important, so I’m glad that it’s prominently
featured in the journal and on their web site.
No comments:
Post a Comment